Westlake Aging Cohort (WeAC)
Condition(s) studied
Study summary
The Westlake Ageing Cohort (WeAC) is a longitudinal cohort study conducted in Hangzhou, Zhejiang Province, China. The investigators aim to enroll 2,800 participants aged 55 years and older for long-term follow-up. The population will include individuals with neurodegenerative diseases or those at the prodromal stage of cognitive impairment, as well as healthy middle-aged and older adults serving as controls. The investigators will collect their sociodemographic, dietary, lifestyle, clinical, and neuroimaging data, as well as biological samples.
Eligibility
Primary outcome measure(s)
- Cognitive function — 48 months
Cognitive function will be evaluated using the Mini-Mental State Examination (MMSE, score range: 0-30, with higher scores indicating better cognitive function) and clinical diagnosis provided by physicians. - Gut microbiome — 48 months
The gut microbiome will be profiled by metagenomic sequencing or ITS rRNA sequencing. In addition, fecal microbiota will be cultured, isolated, and identified.
Trial sites (2)
| Facility | City | Region | Status |
|---|---|---|---|
| Hangzhou First People's Hospital | Hangzhou | Zhejiang | |
| Hangzhou Third People's Hospital | Hangzhou | Zhejiang |
More Westlake University trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07373444 on ClinicalTrials.gov ↗ ← All trials in China